| Recruiting | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis NCT07299019 | Zenas BioPharma (USA), LLC | Phase 3 |
| Not Yet Recruiting | Cladribine Tablets as an Exit Therapy Strategy NCT06887426 | University Hospital, Strasbourg, France | — |
| Active Not Recruiting | A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Scleros NCT06372145 | Sanofi | Phase 3 |
| Completed | A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patient NCT07168694 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration NCT05893225 | University Hospital, Antwerp | Phase 2 |
| Recruiting | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients NCT06292923 | Tiziana Life Sciences LTD | Phase 2 |
| Completed | A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple NCT06395909 | Novartis | — |
| Active Not Recruiting | Functional Outcomes From Diets in Multiple Sclerosis NCT05327322 | University of Alabama at Birmingham | N/A |
| Completed | A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multip NCT06588387 | Novartis | — |
| Completed | Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD2 NCT06526000 | Novartis | — |
| Completed | Novel Imaging Markers in SPMS NCT05357833 | University of Utah | EARLY_Phase 1 |
| Completed | Metformin Treatment in Progressive Multiple Sclerosis NCT05349474 | University of California, Los Angeles | EARLY_Phase 1 |
| Terminated | Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis NCT04925557 | State University of New York at Buffalo | Phase 2 / Phase 3 |
| Withdrawn | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS NCT05029609 | Tiziana Life Sciences LTD | Phase 1 |
| Active Not Recruiting | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis NCT04688788 | Rigshospitalet, Denmark | Phase 3 |
| Completed | Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sc NCT04792567 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo NCT05826028 | Novartis Pharmaceuticals | — |
| Recruiting | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis NCT03783416 | Queen Mary University of London | Phase 1 |
| Recruiting | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Acceptance Based Telephone Support When Transitioning to SPMS NCT04239664 | University of Nottingham | N/A |
| Completed | Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis NCT06360861 | Tehran University of Medical Sciences | Phase 1 |
| Completed | Simvastatin in Secondary Progressive Multiple Sclerosis NCT03896217 | University College, London | Phase 2 |
| Completed | Behavioural Activation for Low Mood in Multiple Sclerosis NCT03935529 | University of Lincoln | N/A |
| Completed | Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis NCT03493841 | Rebecca Spain | Phase 1 |
| Completed | Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis NCT03315923 | Isfahan University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognit NCT03471338 | University Hospital, Caen | N/A |
| Terminated | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis NCT03283826 | Atara Biotherapeutics | Phase 1 / Phase 2 |
| Completed | Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients NCT03282760 | Casa Sollievo della Sofferenza IRCCS | Phase 1 |
| Completed | Mitochondrial Dysfunction and Disease Progression NCT02549703 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Autologous Mesenchymal Stromal Cells for Multiple Sclerosis NCT02495766 | Banc de Sang i Teixits | Phase 1 / Phase 2 |
| Completed | MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial NCT01910259 | University College, London | Phase 2 |
| Completed | Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis NCT02330965 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients NCT02253264 | Johns Hopkins University | Phase 1 |
| Completed | Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis NCT02228213 | Innate Immunotherapeutics | Phase 2 |
| Terminated | Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis NCT02266121 | University Hospital of Mont-Godinne | N/A |
| Terminated | Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis NCT02296346 | University of Utah | N/A |
| Completed | Measuring Active Microglia in Progressive Multiple Sclerosis NCT02207075 | Weill Medical College of Cornell University | — |
| Terminated | ACTH in Progressive Forms of MS NCT01950234 | University of Minnesota | Phase 2 |
| Completed | A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS NCT02208050 | University College Dublin | Phase 4 |
| Completed | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multi NCT01917019 | Biogen | Phase 3 |
| Completed | Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPA NCT01665144 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis NCT01737372 | John F. Foley, MD | — |
| Completed | Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis NCT01684761 | Opexa Therapeutics, Inc. | Phase 2 |
| Completed | Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis NCT01647321 | Johns Hopkins University | N/A |
| Unknown | Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition NCT01466114 | University of California, Los Angeles | Phase 2 |
| Terminated | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Second NCT01416181 | Biogen | Phase 3 |
| Completed | Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS NCT00813969 | The Cleveland Clinic | Phase 1 |
| Withdrawn | Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospi NCT01181089 | Biogen | Phase 1 / Phase 2 |
| Completed | Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis NCT01191996 | Innate Immunotherapeutics | Phase 1 / Phase 2 |
| Completed | Natalizumab Treatment of Progressive Multiple Sclerosis NCT01077466 | Rigshospitalet, Denmark | Phase 2 |
| Completed | Patient Research Cohort: Rapidly Evolving Multiple Sclerosis NCT01044576 | Imperial College London | — |
| Unknown | AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis NCT01228396 | Daval International Limited | Phase 2 |
| Completed | Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis NCT00647348 | Imperial College London | Phase 2 |
| Completed | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) NCT00559702 | Biogen | Phase 1 |
| Terminated | A Study for Patients With Multiple Sclerosis NCT00870155 | Eli Lilly and Company | Phase 2 / Phase 3 |
| Completed | A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis NCT00257855 | University College London Hospitals | Phase 2 |
| Terminated | Study Evaluating Mitoxantrone in Multiple Sclerosis NCT00146159 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | A Study for Patients With Secondary Progressive Multiple Sclerosis NCT00869726 | Eli Lilly and Company | Phase 2 / Phase 3 |